View in EDS HTML Full Text PDF Full Text

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Saved in:
Bibliographic Details
Title: Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Authors: Ferrante, Marc1 (AUTHOR) marc.ferrante@uzleuven.be, Irving, Peter M2 (AUTHOR), Abreu, Maria T3 (AUTHOR), Axler, Jeffrey4 (AUTHOR), Gao, Xiang5 (AUTHOR), Cao, Qian6 (AUTHOR), Fujii, Toshimitsu7 (AUTHOR), Rausch, Astrid8 (AUTHOR), Torres, Joana9,10,11 (AUTHOR), Neimark, Ezequiel12 (AUTHOR), Song, Alexandra12 (AUTHOR), Wallace, Kori12 (AUTHOR), Kligys, Kristina12 (AUTHOR), Berg, Sofie12 (AUTHOR), Liao, Xiaomei12 (AUTHOR), Zhou, Qing12 (AUTHOR), Kalabic, Jasmina13 (AUTHOR), Feagan, Brian14 (AUTHOR), Panaccione, Remo15 (AUTHOR)
Source: Journal of Crohn's & Colitis. Mar2024, Vol. 18 Issue 3, p416-423. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18739946
DOI:10.1093/ecco-jcc/jjad168